Bernstein downgraded Alnylam Pharmaceuticals to Market Perform due to concerns over the design of its TRITON-CM Phase 3 trial for nucresiran, leading to a significantly lowered price target. This downgrade, following a recent stock decline after a disappointing revenue outlook, signals increased risk and reduced future sales expectations for Alnylam.
Bernstein analyst Jeffrey Walch downgraded Alnylam Pharmaceuticals (ALNY) to Market Perform from Outperform, slashing the price target from $376 to $199. The core reason for the downgrade is Alnylam's decision not to modify the design of its TRITON-CM Phase 3 trial for nucresiran, a key next-generation therapeutic. This implies a reduced probability of success for the trial and subsequently lower sales projections for nucresiran, directly impacting Alnylam's future revenue potential. This news exacerbates existing investor concerns, as the downgrade follows a significant stock decline after the company's Q3 earnings report, where its 2026 revenue outlook missed consensus. For traders, this presents a clear negative signal for ALNY in the short-to-medium term, as the market digests increased clinical trial risk and reduced growth prospects.